CAS: 52365-63-6; Dipivefrin

该化合物是一种主要用于眼科治疗青光眼和眼部高血压的合成肾上腺激动剂,是一种肾上腺素,一种主要用于治疗青肿和眼部高血压的合成肾上腺素,一种在身体中代谢后产生肾上腺素,具有治疗作用.Dipivefrin的特征是,它能够比肾上腺素更有效地穿透角膜屏障,提高其眼部生物利用率.该物质通常被作为一种眼滴溶液施用.化学上,它以其微粒酯酯组为人知,有助于其亲性性和稳定性.Dipivefrin行为主要针对α和乙型肾上腺素受体,导致增加水性幽默外流,减少内心压力.其致癌性能包括快速吸收和转化成肾上腺素,其作用时间相对较短.副作用可能包括眼刺激,心率上升和高血压,反映其系统性肾上腺活动.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-7078406-B2
      优先权日:2001-10-09
      标 题 :Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
      发明人:CARVER JR THEODORE E; RINKER JAMES M
      权利人:JOHNSON & JOHNSON PHARM RES
      摘要:The present invention is directed to a compound of Formula I: n nwherein A, R 1 , and R 2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.

      专利号:US-5512577-A
      优先权日:1994-06-02
      标 题:Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions
      发明人:ROCHE VICTORIA F; OHIA S EDET; ROCHE EDWARD B
      权利人:UNIV CREIGHTON
      摘要:The invention relates to the method of synthesis of bicyclic hexahydroaporphine compounds which may provide improved therapy for diseases characterized by an increase in intraocular pressure. More specifically, the present invention relates to the preparation of agents which may provide for improved treatment of patients with glaucoma or ocular hypertension. The present invention describes the intraocular pressure lowering capabilities of several of the bicyclic hexahydroaporphine structures.

      专利号:MX-PA04003451-A
      优先权日:2001-10-09
      标 题:SUBSTITUTED DIFENYLOXAZOLS, THE SYNTHESIS OF THE SAME AND THE USE OF THE SAME AS FLUORESCENCE DETECTORS.

      专利号:US-2007148246-A1
      优先权日:2005-08-11
      标题:Nucleic Acid-Based Matrixes
      发明人:LUO DAN; LI YOUGEN
      权利人:LUO DAN; LI YOUGEN
      摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

      专利号:US-2014315720-A1
      优先权日:2012-10-24
      标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
      发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
      权利人:CELANESE ACETATE LLC
      摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

      专利号:US-8486621-B2
      优先权日:2005-08-11
      标题 :Nucleic acid-based matrixes
      发明人:LUO DAN; UM SOONG HO
      权利人:LUO DAN; UM SOONG HO; CORNELL RES FOUNDATION INC
      摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include cell-free protein synthesis.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Groh MJ, Michelson G, Harazny J, Groh M, Koschinsky K. [Changes in retinal blood flow by topical administration of 0.1% dipivefrin]. Ophthalmologe. 1999 Nov;96(11):706-10. German. Erratum in: J Ocul Pharmacol 1993 Winter;9(4):385. French. German. German.

      合成参考文献


      参考文献:10.2165/00002512-199914050-00006
      摘要:Lindén C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999 May;14(5):387–98. doi: 10.2165/00002512-199914050-00006.
      参考文献:10.1007/s10792-018-0938-7
      摘要:Scuderi G, Contestabile MT, Scuderi L, Librando A, Fenicia V, Rahimi S. Pigment dispersion syndrome and pigmentary glaucoma: a review and update. International Ophthalmology. 2018 May 02;39(7):1651–62. doi: 10.1007/s10792-018-0938-7.
      参考文献:10.1007/bf00186578
      摘要:Mwinula JH, Sagawa T, Tawara A, Inomata H. Anterior chamber angle vascularization in Sturge-Weber syndrome Report of a case. Graefe's Archive for Clinical and Experimental Ophthalmology. 1994 Jul;232(7):387–91. doi: 10.1007/bf00186578.
      参考文献:10.1111/j.1600-0420.1995.tb00323.x
      摘要:Estil S, Haaskjold E, Bjerknes R, Refsum SB. Early cell kinetic effects of some drugs on the rat corneal and conjunctival epithelia. Acta Ophthalmol Scand. 1995 Dec;73(6):496–500. doi: 10.1111/j.1600-0420.1995.tb00323.x.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知